Izotropic Corp. · CSE:IZO
Izotropic — Investor Presentation (May 2022)
26 slides from Izotropic's investor presentation, May 2022
Slide 1: Investor Presentation
,�, ,;,-..-. ........ \(,__.-, ..�r# C O R P O R A T I ON INVESTOR PRESENTATION Scan or Click to For 11/usr rat1ve purposes only. tzoV, ew ,s nor yet approved for sale Watch lzoView in Action! CSE: 120 OTCQB: IZOZF BREAST CT IMAGING
Slide 2: Izotropic Overview
IZOTROPIC OVERVIEW for the more accurate detection and diagnosis of breast cancers. BREAST CT EVOLUTION GROWING MARKET ¢ $20M spent on R&D to date via ¢ Breast imaging market growing from government grants $3.7B to $5.4B by 2025 * Performing prototypes and * Imaging and diagnostic procedure ongoing
Slide 3: 5th Generation Device
Zz CZ WZ Y Zz \\ a eeN = 5TH GENERATION DEVICE First device for commercialization Proof of Concept Units by Dr. John M. Boone at UC Davis « Four successive laboratory prototypes * Over 600 patients imaged in a clinical study validating the technology ¢ Second ongoing clinical study with 400 patients
Slide 4: 2021 Best New Radiology Device Award Semifinalist
2021 BEST NEW RADIOLOGY DEVICE AWARD SEMIFINALIST Izotropic's IzoView Breast CT System Auntminnie.com, a leading radiology news website, has recognized Izotropic's lzoView Breast CT System in the Best New Radiology Device category in September 2021. AuntMinnie.com THE BEST OF RADIOLOGY SEMIFINALIST
Slide 5: Licensed Technology & Intellectual Property
By Jy FER LICENSED TECHNOLOGY & INTELLECTUAL PROPERTY GLOBAL LICENSING RIGHTS ¢ Exclusive worldwide licensing rights to Breast CT through an agreement with The Regents of The University of California ¢ Developed over 20 years by principal technology founder and company director Dr. John M. Boone ¢ C
Slide 6: True 3D Breast CT Imaging
TRUE 3D BREAST CT IMAGING CSE: 1Z0 OTCQB: IZOZF IzoView produces high resolution breast images in true 3D and is ideal for imaging patients with dense breast tissue. A single 10 second scan acquires approximately 500 images, without painful breast compression or continual technician breast handling,
Slide 7: Breast Cancer Is Now the Most Common Form
A y BREAST CANCER IS NOW THE MOST COMMON FORM U.S. Breast Cancer Landscape Facts. 41M BREASTS SCANS IN 2019 ¢ Screening mammography misses 1/ 5 cancers * >8,500 MSQA Certified imaging centers and >23,000 mammography and tomosynthesis certified units installed * Cost of follow-up diagnostic imaging a
Slide 8: Diagnostic Mammography Challenges
DIAGNOSTIC MAMMOGRAPHY CHALLENGES zu Limitations of the current standard of care. CONTINUAL BREAST COMPRESSION * Technician manipulation of the breast for multiple imaging views * 46% of patient non-compliance is due to pain * Concerns with breast implants (ie. discomfort and rupture) REQUIRES TECHN
Slide 9: Digital Breast Tomosynthesis
DIGITAL BREAST TOMOSYNTHESIS Sy Latest improvement to the standard of care. The limitations of diagnostic mammography remain. Digital breast tomosynthesis adds 15- 50 degrees of image acquisition range (depending on the model of machine) which improves detection. However, increased acquisition time
Slide 10: IzoView Breast CT
IZOVIEW BREAST CT ii) A whole new experience for patients, radiologists and providers. NO BREAST COMPRESSION Natural breast orientation preserved, no pain or discomfort, very comfortable face down view, excellent visualization with contrast PATIENT EMPOWERMENT Patient places own breast in imaging cu
Slide 11: Solving an Unmet Need
SOLVING AN UNMET NEED Ay Image Acquisition Matters. on ° Mammography Tomosynthesis Ww | ZovVi eW 0° 15° - 50° 360° 2D Image 2.5D Image True 3D, 500 slices 1 of the image slices CSE: 1Z0 OTCQB: IZOZF BREAST CT IMAGING - 11
Slide 12: Solving an Unmet Need
SOLVING AN UNMET NEED Images below are of the same breast. Mammography Tomosynthesis 2D Image 2.5D Image True 3D, 360
Slide 13: Clinical Studies
N\\}, \\ Fy CLINICAL STUDIES eee ~~ = awn ES INITIAL CLINICAL STUDY DESIGN FOLLOW-ON CLINICAL STUDIES To expedite patient and provider access to IzoView, the Platform applications will be validated in follow-on clinical initial clinical study will demonstrate superior studies including breast screen
Slide 14: IzoView Platform Uses
IZOVIEW PLATFORM USES Making Breast CT an indispensable tool for improving the out comes of br. STEPS TO TREATMENT: PLATFORM PRODUCTS: SALES MODELS: CSE: IZO OTCQB: IZ0ZF SCREENING —_ DIAGNOSTIC BIOPSY TREATMENT NEW INDICATIONS INITIAL REGULATORY NEW ACCESSORIES FO! CUS © ONE TIME, RENTAL, ONE TIME
Slide 15: Market Acceptance
MARKET ACCEPTANCE Customers are asking for IzoView today. PATIENTS Breast CT can create a better experience for wider patient adoption DOCTORS 3D visualization capabilities and the use of contrast expands use cases HOSPITALS & CLINICS Can improve throughput and attract more patients INSURANCE PAYORS
Slide 16: Broad Engagement Preparing for Market
BROAD ENGAGEMENT PREPARING FOR MARKET Near-term catalysts across multiple workstreams. DEVELOPMENT « Al software modules and hardware accessories to expand IzoView platform * Partnerships to accelerate product development: Deep-learning machine algorithms with Johns Hopkins University School of Medi
Slide 17: Directors & Management
Yh DIRECTORS & MANAGEMENT aw JOHN MCGRAW, PHD Director & CEO Executive in imaging, diagnostic service, and medical device public JOHN M. BOONE, PHD Founder & Director Medical Physicist, Professor, global speaker, text book YOUNES ACHKIRE, PHD EVP Product Engineering Medical device R&D expert, managi
Slide 18: Dr. John Boone
DR. JOHN BOONE Principal Founder of Breast CT Technology & Director "We scanned the first patient using cone beam breast CT in 2004, scanned the first cancer patient in early 2005, and performed the first contrast - enhanced breast CT exam in 2006. | take my cues from the breast imaging radiologists
Slide 19: Dr. John McGraw
DR. JOHN MCGRAW Chief Executive Officer "High resolution breast imaging is critical to identifying malignancies as early as possible. Izotropic’s Breast CT has the opportunity to offer patients, with or without dense breasts, a single rapid scan for breast cancer detection in complete comfort and di
Slide 20: Dr. Younes Achkire
DR. YOUNES ACHKIRE Executive Vice President of Product Engineering "As a medtech engineering executive with decades of experience, | know the potential Izoview has to disrupt the world of breast imaging. With my expertise in developing high precision equipment, | will engineer novelties in Izoview t
Slide 21: Dr. Andrew Hernandez
DR. ANDREW HERNANDEZ Head of Imaging Technology "The IzoView breast CT system will fully harness the capabilities of advanced x-ray imaging hardware and is designed to provide exceptional image quality for the detection and diagnosis of breast cancer while minimizing imaging time, pain and discomfor
Slide 22: Medical & Scientific Advisors
DR. MARTIN YAFFE, PHD University of Toronto, SunnyBrook Hospital Drove the development of digital mammography, Member of The Order of Canada DR. KAREN LINDFORS MD, MPH, FACR UC Davis Highly published leading advocate for women's health and xpert in the field of breast cancer screening and breast ima
Slide 23: Market Capitalization
MARKET CAPITALIZATION 044) May 12, 2022 52 WEEK RANGE - CSE: CAD $0.53 - 1.24 52 WEEK RANGE - OTC US $0.40 - $1.07 52 WEEK RANGE - FSE: EUR $0.40 - $0.81 COMMON SHARES ISSUED - BASIC: 44,841,454 WARRANTS: 4,350,000 @ $0.20 WARRANTS: 6,356,100 @ $0.75 WARRANTS: 1,896,679 @ $1.50 WARRANTS: 62,937 @ $1
Slide 24: Legal
LEGAL SECURITIES COUNSEL: CLARK WILSON LLP https://www.cwilson.com TRUST AGENT: ODYSSEY TRUST https://odysseytrust.com U.S. PATENT COUNSEL: VENABLE LLP https://www.venable.com REGULATORY COUNSEL: BROOKE CONSULTING LLC https://www.brooke-consulting.com CSE: 1ZO OTCQB: IZOZF BREAST CT IMAGING - 24
Slide 25: Disclaimer
DISCLAIMER This document may contain.statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates.
Slide 26: Investor Relations
�- �---� --� ....... ..... ·, INVESTOR RELATIONS: \�� C O R P O R A T I O N [email protected] 1-833-IZOCORP James Berrard ext.1 Tyler Muir ext.2 GENERAL INQUIRIES [email protected] 1-833-IZOCORP ext. 3 � @IZOTROPIC O@IZOTROPIC DD @IZOTROPIC WHATSAPP MESSAGE 1zocorp.com For 11/usr rat1ve purposes only. l